• Spasmo-Urgenin indications
• Uses of Spasmo-Urgenin in details
• Spasmo-Urgenin description
• Spasmo-Urgenin dosage
• Spasmo-Urgenin interactions
• Spasmo-Urgenin side effects
• Spasmo-Urgenin contraindications

What is Spasmo-Urgenin?

Spasmo-Urgenin is used to treat the symptoms of an overactive bladder, such as a frequent need to urinate or incontinence (loss of bladder control). It helps to relax the muscles in the bladder and reduce the daily episodes of incontinence. Spasmo-Urgenin is a urinary antispasmodic agent.

Spasmo-Urgenin is available only with your doctor's prescription.

Spasmo-Urgenin indications

Spasmo-Urgenin Extended-Release Capsules are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

How should I use Spasmo-Urgenin?

Use Spasmo-Urgenin extended-release capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with Spasmo-Urgenin extended-release capsules. Talk to your pharmacist if you have questions about this information.
• Take Spasmo-Urgenin extended-release capsules by mouth with water on an empty stomach at least 1 hour before eating, preferably in the morning or as directed by your doctor.
• If you miss a dose of Spasmo-Urgenin extended-release capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Spasmo-Urgenin extended-release capsules.

Uses of Spasmo-Urgenin in details

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, Spasmo-Urgenin improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. Spasmo-Urgenin belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

How to use Spasmo-Urgenin

Read the Patient Information Leaflet provided by your pharmacist before you start using Spasmo-Urgenin and each time you get a refill. If you have any questions, consult your doctor or pharmacist.

Take this medication by mouth on an empty stomach at least 1 hour before a meal, usually once daily or as directed by your doctor.

Swallow the capsule whole. Do not crush or chew the capsule. Also avoid drinking alcohol or taking any product containing alcohol for 2 hours before and after taking this medication. Alcohol can destroy the long action of the drug and may increase side effects.

If you cannot swallow the capsule, you may open the capsule and place the beads in a small amount of water or directly onto the tongue. Do not crush or chew the beads because doing so may cause the drug to be released too quickly, increasing side effects. Swallow all of the beads right away.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day. Dosage is based on your medical condition and response to treatment.

Tell your doctor if your condition does not improve or if it worsens.

Spasmo-Urgenin description

Spasmo-Urgenin is a urinary antispasmodic. It is sold under the brand name Sanctura in the US, and as Trosec in Canada. [Wikipedia]

Spasmo-Urgenin dosage

Spasmo-Urgenin Dosage

Generic name: Spasmo-Urgenin 60mg

Dosage form: capsule, extended release

See also:

• Sanctura tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

The recommended dosage of Spasmo-Urgenin® is one 60 mg capsule daily in the morning. Spasmo-Urgenin® capsules should be dosed with water on an empty stomach, at least one hour before a meal.

Spasmo-Urgenin® is not recommended for use in patients with severe renal impairment (creatinine clearance less than 30 mL/minute).

More about Spasmo-Urgenin (Spasmo-Urgenin)

• Side Effects
• During Pregnancy
• Dosage Information
• Drug Images
• Drug Interactions
• Support Group
• En Espanol
• 7 Reviews - Add your own review/rating

Consumer resources

• Spasmo-Urgenin extended-release capsules
• Spasmo-Urgenin

Professional resources

• Spasmo-Urgenin (FDA)
• Spasmo-Urgenin (AHFS Monograph)

Other formulations

• Sanctura

Related treatment guides

• Interstitial Cystitis
• Overactive Bladder
• Urinary Incontinence

Spasmo-Urgenin interactions

See also:
What other drugs will affect Spasmo-Urgenin?

Spasmo-Urgenin is metabolized by ester hydrolysis and excreted by the kidneys through a combination of tubular secretion and glomerular filtration. Based on in vitro data, no clinically relevant metabolic drug-drug interactions are anticipated with Spasmo-Urgenin®. However, some drugs which are actively secreted by the kidney may interact with Spasmo-Urgenin® by competing for renal tubular secretion.

The concomitant use of Spasmo-Urgenin® with other antimuscarinic agents that produce dry mouth, constipation, and other anticholinergic effects may increase the frequency and/or severity of such effects. Spasmo-Urgenin® may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility.

Digoxin

Concomitant use of Spasmo-Urgenin 20mg twice daily and digoxin did not affect the pharmacokinetics of either drug.

Antacid

While the systemic exposure of Spasmo-Urgenin on average was comparable with and without antacid containing aluminum hydroxide and magnesium carbonate, 5 out of 11 individuals in a drug interaction study demonstrated either an increase or decrease in Spasmo-Urgenin exposure, in presence of antacid. The clinical relevance of these findings is not known.

Metformin

Co-administration of 500 mg metformin immediate release tablets twice daily reduced the steady-state systemic exposure of Spasmo-Urgenin by approximately 29% for mean AUC and by 34% for mean Cmax. The effect of a decrease in Spasmo-Urgenin exposure on the efficacy of Spasmo-Urgenin® is unknown. The steady-state pharmacokinetics of metformin were comparable when administered with or without 60 mg Spasmo-Urgenin® once daily under fasted condition. The effect of metformin at higher doses on Spasmo-Urgenin PK is unknown.

Spasmo-Urgenin side effects

See also:
What are the possible side effects of Spasmo-Urgenin?

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of Spasmo-Urgenin was evaluated in controlled clinical trials in a total of 2975 patients, who were treated with Spasmo-Urgenin (N=1673), placebo (N=1056) or active control medications (N=246). Of this total, 1181 patients participated in two, 12-week, U.S., efficacy and safety studies and a 9-month open-label extension. Of this total, 591 patients received Spasmo-Urgenin tablets 20 mg twice daily. In all controlled trials combined, 232 and 208 patients received treatment with Spasmo-Urgenin for at least 24 and 52 weeks, respectively.

In all placebo-controlled trials combined, the incidence of serious adverse events was 2.9% among patients receiving Spasmo-Urgenin tablets 20 mg twice daily and 1.5% among patients receiving placebo. Table 1 lists adverse reactions from the combined 12-week U.S. safety and efficacy trials were reported by at least 1% of patients, and were reported more frequently in the Spasmo-Urgenin group than in the placebo group.

The two most common adverse reactions reported by patients receiving Spasmo-Urgenin tablets 20 mg twice daily were dry mouth and constipation. The single most frequently reported adverse reaction for Spasmo-Urgenin, dry mouth, occurred in 20.1% of Spasmo-Urgenin treated patients and 5.8% of patients receiving placebo. In the two U.S. studies, dry mouth led to discontinuation in 1.9% of patients treated with Spasmo-Urgenin tablets 20 mg twice daily. For the patients who reported dry mouth, most had their first occurrence of the event within the first month of treatment.

Table 1. Incidence (%) of adverse reactions with Spasmo-Urgenin, reported in greater than or equal to 1% of all patients treated with Spasmo-Urgenin and more frequent with Spasmo-Urgenin tablets (20 mg twice daily) than placebo in Studies 1 and 2 combined

Other adverse reactions from the U.S., placebo-controlled trials, occurring in greater than or equal to 0.5% and less than 1.0% of Spasmo-Urgenin treated patients, and more common with Spasmo-Urgenin than placebo are: tachycardia, vision blurred, abdominal distension, vomiting, dysgeusia, dry throat, and dry skin.

During controlled clinical studies, one adverse reaction of angioneurotic edema was reported.

Post-marketing Experience

The following adverse reactions have been identified during post-approval use of Spasmo-Urgenin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal – gastritis; Cardiovascular – palpitations, supraventricular tachycardia, chest pain, syncope, “hypertensive crisis”; Immunological – Stevens-Johnson syndrome, anaphylactic reaction, angioedema; Nervous System – dizziness, confusion, vision abnormal, hallucinations, somnolence and delirium; Musculoskeletal – rhabdomyolysis; General – rash.

Spasmo-Urgenin contraindications

See also:
What is the most important information I should know about Spasmo-Urgenin?

You should not take this medicine if you are allergic to Spasmo-Urgenin, or if you have untreated or uncontrolled narrow-angle glaucoma, a blockage in your digestive system, or if you are unable to urinate.

Take Spasmo-Urgenin on an empty stomach, at least 1 hour before a meal.

Avoid drinking alcohol within 2 hours before or after you take Spasmo-Urgenin. Drinking alcohol can increase certain side effects of Spasmo-Urgenin.

This medication may cause blurred vision and may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert and able to see clearly.

Avoid becoming overheated or dehydrated during exercise and in hot weather. Spasmo-Urgenin can decrease sweating, which makes it easier for you to have heat stroke. Drink plenty of fluids while you are taking this medication.

Before using Spasmo-Urgenin, tell your doctor if you regularly use other medicines that make you sleepy (such as cold or allergy medicine, sedatives, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by Spasmo-Urgenin.

Active ingredient matches for Spasmo-Urgenin:

Trospium in Austria, Bahrain, Egypt, Kuwait, Qatar, Saudi Arabia, United Arab Emirates.

Trospium Chloride in Thailand.

Echinacea angustifolia/saw palmetto/Trospium chloride in Spain, Austria, Thailand.

Echinacea extr/Sabal extr/trospium Cl in Thailand.

Echinacea/saw palmetto/Trospium chloride in South Africa.

References

1. DailyMed. "TROSPIUM CHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubChem. "Trospium". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
3. DrugBank. "Trospium". http://www.drugbank.ca/drugs/DB00209 (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology